Risk of vancomycin-induced nephrotoxicity in the population with chronic kidney disease

American Journal of the Medical Sciences

Volumn 345, Issue 5, 2013, Pages 396-399

  Panwar, Bhupesh ^a   Johnson, Victoria A ^a,b   Patel, Mukesh ^a,b   Balkovetz, Daniel F ^a,b  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Acute renal failure; Antibiotics; Dialysis; MRSA

Indexed keywords

VANCOMYCIN;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; DRUG MONITORING; HUMAN; MORBIDITY; MORTALITY; NEPHROTOXICITY; NOMOGRAM; RENAL REPLACEMENT THERAPY; REVIEW; STAPHYLOCOCCUS INFECTION; VANCOMYCIN INDUCED NEPHROTOXICITY;

EID: 84876826151     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318268023d     Document Type: Review

References (44)

1. Hsu CY, Ordonez JD, ChertowGM, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 2008;74:101-7.
2. Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 2008;3:844-61.
3. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320:143-9.
4. Browner WS, Li J, Mangano DT. In-hospital and long-term mortality in male veterans following noncardiac surgery. The Study of Perioperative Ischemia Research Group. JAMA 1992;268:228-32.
5. Singh P, Rifkin DE, Blantz RC. Chronic kidney disease: An inherent risk factor for acute kidney injury? Clin J Am Soc Nephrol 2010;5: 1690-5.
6. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005;294:813-8.
7. Lines SW, Cherukuri A, Murdoch SD, et al. The outcomes of critically ill patients with acute kidney injury receiving renal replacement therapy. Int J Artif Organs 2011;34:2-9.
8. Levine DP. Vancomycin: A history. Clin Infect Dis 2006;42(suppl 1): S5-12.
9. Geraci JE, Heilman FR, Nichols DR, et al. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Antibiot Annu 1956-1957:90-106.
10. Darko W, Medicis JJ, Smith A, et al. Mississippi mud no more: Costeffectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 2003;23:643-50.
11. US Food and Drug Administration. FDA statement about product quality of parenteral vancomycin products. 2012. http://www.fda.gov/-Drugs/DrugSafety/ ucm295414.htm. Accessed March 14, 2012.
12. Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25:679-87.
13. Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-6.
14. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity, Antimicrob Agents Chemother 1999;43:1549-55.
15. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 2006;166:2138-44.
16. Ingram PR, Lye DC, Tambyah PA, et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008;62:168-71.
17. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-14.
18. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children: Executive summary. Clin Infect Dis 2011;52:285-92.
19. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-20.
20. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
21. Clemens EC, Chan JD, Lynch JB, et al. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2011;71:408-14.
22. Kullar R, Davis SL, Taylor TN, et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy 2012;32:195-201.
23. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis 1994; 18:533-43.
24. Dieterich C, Puey A, Lin S, et al. Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol Sci 2009;107: 258-69.
25. Celik I, Cihangiroglu M, Ilhan N, et al. Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. Basic Clin Pharmacol Toxicol 2005;97:325-32.
26. King DW, Smith MA. Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol In Vitro 2004;18:797-803.
27. Nishino Y, Takemura S, Minamiyama Y, et al. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Radic Res 2003;37:373-9.
28. Le Moyec L, Racine S, Le Toumelin P, et al. Aminoglycoside and glycopeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine. Crit Care Med 2002;30: 1242-5.
29. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993;37: 1563-71.
30. Cutler NR, Narang PK, Lesko LJ, et al. Vancomycin disposition: The importance of age. Clin Pharmacol Ther 1984;36:803-10.
31. Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 1988;43:565-70.
32. Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984;25:433-7.
33. Golper TA, Wedel SK, Kaplan AA, et al. Drug removal during continuous arteriovenous hemofiltration: Theory and clinical observations. Int J Artif Organs 1985;8:307-12.
34. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11:257-82.
35. Krogstad DJ, Moellering RC Jr, Greenblatt DJ. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol 1980;20:197-201.
36. Marre R, Schulz E, Anders T, et al. Renal tolerance and pharmacokinetics of vancomycin in rats. J Antimicrob Chemother 1984;14:253-60.
37. Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: A nomogram for dosage. Ann Intern Med 1981;94:343-6.
38. Macias WL, Mueller BA, Scarim SK. Vancomycin pharmacokinetics in acute renal failure: Preservation of nonrenal clearance. Clin Pharmacol Ther 1991;50:688-94.
39. Rotschafer JC, Crossley K, Zaske DE, et al. Pharmacokinetics of vancomycin: Observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982;22:391-4.
40. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988;32:848-52.
41. Brown DL, Mauro LS. Vancomycin dosing chart for use in patients with renal impairment. Am J Kidney Dis 1988, 11:15-9.
42. Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int 2010;77:760-4.
43. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
44. Earley A, Miskulin D, Lamb EJ, et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: A systematic review. Ann Intern Med 2012;156:785-95.